Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

By D. Cherney, B. Perkins, Nima Soleymanlou, M. Maione, V. Lai, Alana Lee, N. Fagan, H. Woerle, O. Johansen, U. Broedl and 1 more. Circulation, 2014

1,183 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017, background): “Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reduct”
Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes – Mechanisms, Management, and Clinical Considerations (2016, neutral): “Other potential mechanisms remain speculative including potential secondary effects on SGLT1(380) and effects on mineralocorticoid metabolism.(377) Whether this beneficial effect on cardiovascular outcomes is a class effect or a drug effect is unknown, and results of other cardiovascular outcome tri”
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials (2017, background): “Further studies are warranted to explore the utility and establish the safety of empagliflozin in the treatment of T1DM, especially in light of DKA cases reported in clinical trials in T1DM [72, 73].”